AnalystsJames CondulisJames Condulis's Stock Forecasts
AnalystsJames Condulis
Sectors:
Industries:
Analyst Ranking
Top 38%
#1891 out of 5087 analysts
Average Return
+26.41%
Win Rate
67%4 out of 6
Risk vs Reward
Poor
Good
James Condulis's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Newamsterdam Pharma Co NvNAMS | +73.76% | $21.84 | $37.95 | 2025-06-10 - 2025-10-31 | Strong Buy |
Soleno Therapeutics IncSLNO | +49.28% | $44.99 | $67.16 | 2025-03-05 - 2025-10-31 | Strong Buy |
Cytokinetics IncCYTK | +35.82% | $46.82 | $63.59 | 2025-01-22 - 2025-10-31 | Strong Buy |
Cytokinetics IncCYTK | +28.15% | $49.62 | $63.59 | 2025-09-02 - 2025-10-31 | Strong Buy |
James Condulis Analyst Color
Get additional color on James Condulis's coverage of popular stocks
James Condulis's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Aardvark Therapeutics IncAARD | 1 | Strong Buy | $24.00 | +124.51% | Initiates Coverage On | a month ago |
Cytokinetics IncCYTK | 2 | Strong Buy | $96.00 | +50.97% | Maintains | 2 months ago |
Newamsterdam Pharma Co NvNAMS | 1 | Strong Buy | $44.00 | +15.94% | Initiates Coverage On | 5 months ago |
Soleno Therapeutics IncSLNO | 2 | Strong Buy | $108.00 | +60.81% | Maintains | 7 months ago |
Edgewise Therapeutics IncEWTX | 1 | Hold | $30.00 | +64.11% | Initiates Coverage On | 9 months ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.